ReviewMarine drugs2022
Cryptic Metabolites from Marine-Derived Microorganisms Using OSMAC and Epigenetic Approaches.
Review in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 72 citations in OpenAlex.
- Enhancing 3-O-methylfunicone production by endophytic Talaromyces pinophilus J6 through culture optimization and its anti-Helicobacter pylori activity.Archives of microbiology · 2026Article
- Metabolite diversification via halogen salts enhances biocontrol potential of marine-derived Trichoderma virens B211.Natural products and bioprospecting · 2026Article
- Discovery of New Zosteropenillines from the Seagrass-Derived FungusMarine drugs · 2026Article
- Article
- Harnessing Endophytic Fungi as a Sustainable Source of Novel Anticancer Agents: Opportunities, Challenges, and Future Directions.Molecules (Basel, Switzerland) · 2026Review
- Cytotoxic Curvalarol C and Other Compounds from Marine FungusMolecules (Basel, Switzerland) · 2025Article
- Article
- Epigenetic modulation of Ceratorhiza hydrophila by 5-azacytidine enhances antifungal metabolite production: insights from antimicrobial, metabolic, genomic and computational analyses.BMC microbiology · 2025Article
- An OSMAC Strategy for the Production of Antimicrobial Compounds by the Amazonian FungiAntibiotics (Basel, Switzerland) · 2025Article
- Total Synthesis of (+)-Penicyclone A and Evaluation of Biological Activity Including Intermediate Compounds.International journal of molecular sciences · 2025Article
- Peptides in plant-microbe interactions: Functional diversity and pharmacological applications.Cell surface (Amsterdam, Netherlands) · 2025Review
- Exploring the modern approaches to enhance fungal endophyte-derived bioactive secondary metabolites.3 Biotech · 2025Review
- The Cytotoxic Activity of Secondary Metabolites from Marine-DerivedMarine drugs · 2025Review
- Antifungal Volatile Organic Compounds fromJournal of fungi (Basel, Switzerland) · 2025Article
- Bioactive Secondary Metabolites from an Arctic Marine-Derived Strain,Molecules (Basel, Switzerland) · 2025Article
- SORBS3-β suppresses lymph node metastasis in cervical cancer by promoting the ubiquitination of β-catenin.Journal of translational medicine · 2025Article
- Last Decade Insights in Exploiting Marine Microorganisms as Sources of New Bioactive Natural Products.Marine drugs · 2025Review
- Marine Fungi: A Prosperous Source of Novel Bioactive Natural Products.Current medicinal chemistry · 2025Review
- Isolation of marine-derived filamentous fungi and their potential application for bioremediation process.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- New piperazine derivatives helvamides B-C from the marine-derived fungus Penicillium velutinum ZK-14 uncovered by OSMAC (One Strain Many Compounds) strategy.Natural products and bioprospecting · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Marine microorganisms have proven to be a source of new natural products with a wide spectrum of biological activities relevant in different industrial sectors. The ever-increasing number of sequenced microbial genomes has highlighted a discrepancy between the number of gene clusters potentially encoding the production of natural products and the actual number of chemically characterized metabolites for a given microorganism. Homologous and heterologous expression of these biosynthetic genes, which are often silent under experimental laboratory culture conditions, may lead to the discovery of new cryptic natural products of medical and biotechnological interest. Several new genetic and cultivation-based strategies have been developed to meet this challenge. The OSMAC approach (one strain-many compounds), based on modification of growth conditions, has proven to be a powerful strategy for the discovery of new cryptic natural products. As a direct extension of this approach, the addition of chemical elicitors or epigenetic modifiers have also been used to activate silent genes. This review looks at the structures and biological activities of new cryptic metabolites from marine-derived microorganisms obtained using the OSMAC approach, the addition of chemical elicitors, and enzymatic inhibitors and epigenetic modifiers. It covers works published up to June 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.